<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41923">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988324</url>
  </required_header>
  <id_info>
    <org_study_id>2012.2708</org_study_id>
    <nct_id>NCT01988324</nct_id>
  </id_info>
  <brief_title>AR and ER Imaging in Metastatic Breast Cancer</brief_title>
  <official_title>Androgen Receptor and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.A.P. Hospers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knowledge of breast cancer estrogen receptor (ER) expression is of major importance in
      treatment-decision making. Patients with ER-positive tumors can be treated with
      anti-oestrogen therapy, which has relatively few side effects compared to chemotherapy.
      Whole-body tumor ER-expression can be visualized by 18F-fluoroestradiol PET imaging
      (FES-PET). In addition to ER, the androgen receptor (AR) is a potential new target in breast
      cancer. PET imaging with 18F-fluorodihydrotestosterone (18F-FDHT) may allow visualization of
      tumor AR-expression. In the current study we will perform FES-PET and FDHT-PET in metastatic
      breast cancer patients and evaluate the concordance with concurrent biopsies. Molecular
      imaging of tumor AR- and ER-expression may well be of value for future treatment
      decision-making.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Concordance between PET results and immunohistochemistry on biopsied lesions</measure>
    <time_frame>within two months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the concordance between PET (with 18F-FDHT and 18F-FES), and immunohistochemistry (for AR and ER) on concurrent (within 8 weeks) tumor biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of lesions detected on PET imaging compared to CT-scan and bone scintigraphy.</measure>
    <time_frame>within six weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-patient variation in tracer uptake.</measure>
    <time_frame>within six weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-observer variation in FES PET and FDHT PET results in two independent observers.</measure>
    <time_frame>approximately two months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FDHT-PET scan</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FES-PET scan</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CT-scan</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone scintigraphy</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor biopsy</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Metastatic breast cancer, with at least one known metastasis outside of the liver

          2. Presence of a lesion that is safely accessible for tumor biopsy (may be liver lesion)

          3. Postmenopausal status defined as one of the following:

               -  age ≥60 years

               -  previous bilateral oophorectomy

               -  age &lt;60 years and amenorrhea for &gt;12 months in the absence of interfering
                  hormonal therapies (such as LH-RH agonists and ER-antagonists)

               -  patients age &lt;60 years using an ER-antagonist should have amenorrhea for &gt; 12
                  months and FSH &gt;24 U/L and LH &gt;14 U/L e. patient age &lt;60 years using LH-RH
                  agonists should continue LH-RH-agonists until after the PET procedures

          4. Initially ER-positive tumor histology.

          5. ECOG performance status 0-2.

          6. Signed written informed consent

          7. Able to comply with the protocol

        Exclusion Criteria:

          1. Use of estrogen receptor ligands, including tamoxifen, fulvestrant or estrogens, or
             androgen receptor ligands, during the 6 weeks before entry into the study

          2. Life-expectancy ≤ 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Geke AP Hospers, MD PhD</last_name>
    <phone>+31 503612775</phone>
    <email>g.a.p.hospers@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Epi Boven, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>G.A.P. Hospers</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
